Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score

Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma

(2016) Michaela L. Tsai et al.   Clinical Breast Cancer

Comprehensive Histologic Scoring to Maximize the Predictability of Pathology-generated Equation of Breast Cancer Oncotype DX Recurrence Score

(2016) Thaer Khoury et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Comparison of Oncotype DX Recurrence Score by Histologic Types of Breast Carcinoma

(2015) Philip E. Bomeisl et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Is There a Role for Oncotype Dx Testing in Invasive Lobular Carcinoma?

(2015) Niamh Conlon et al.   Breast Journal

Indications for Prognostic Gene Expression Profiling in Early Breast Cancer

(2015) Erin F. Cobain et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score

(2015) Bradley M Turner et al.   MODERN PATHOLOGY

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

(2015) Joseph A. Sparano et al.   NEW ENGLAND JOURNAL OF MEDICINE

In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy?

(2015) X. Pivot et al.   ONCOLOGIST

Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective Study

(2015) Rumiko Tashima et al.   PLoS One

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

(2011) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing?

(2011) K. H. Allison et al.   BREAST CANCER RESEARCH AND TREATMENT

Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score

(2011) S Sahebjam et al.   BRITISH JOURNAL OF CANCER

Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer

(2011) Jack Cuzick et al.   JOURNAL OF CLINICAL ONCOLOGY

Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20

(2010) Eleftherios P. Mamounas et al.   JOURNAL OF CLINICAL ONCOLOGY

Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer

(2010) REIKI NISHIMURA et al.   Experimental and Therapeutic Medicine